Pages that link to "Q89120437"
Jump to navigation
Jump to search
The following pages link to Clinical response of the novel activating ALK-I1171T mutation in neuroblastoma to the ALK inhibitor ceritinib (Q89120437):
Displaying 9 items.
- Low Frequency ALK Hotspots Mutations In Neuroblastoma Tumours Detected By Ultra-deep Sequencing: Implications For ALK Inhibitor Treatment (Q64252659) (← links)
- The pan-cancer landscape of prognostic germline variants in 10,582 patients (Q89746478) (← links)
- Targeting anaplastic lymphoma kinase in neuroblastoma (Q91895786) (← links)
- Repotrectinib (TPX-0005), effectively reduces growth of ALK driven neuroblastoma cells (Q92095846) (← links)
- Alectinib, an Anaplastic Lymphoma Kinase Inhibitor, Abolishes ALK Activity and Growth in ALK-Positive Neuroblastoma Cells (Q92110305) (← links)
- Integrative discovery of treatments for high-risk neuroblastoma (Q92407109) (← links)
- Use of the cell division assay to diagnose Fanconi anemia patients' hypersensitivity to mitomycin C (Q98781888) (← links)
- Identification of the Wallenda JNKKK as an Alk suppressor reveals increased competitiveness of Alk-expressing cells (Q99365542) (← links)
- ALK I1171T (Q107522020) (← links)